People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AlphaTON Capital Corp | — | Pharmaceuticals | Series B | $70.7M | $158.9M | 2022 |
James M. Mellon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James M. Mellon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Mellon | 1 | 10 |
| Gregory Bailey | 1 | 8 |
| Robert Kramer | 1 | 5 |
| Steven Mintz | 1 | 3 |
| Brittany Kaiser | 1 | 2 |
| Alexander Pickett | 1 | 2 |
| Steven B. Mintz | 1 | 1 |
| Linda M. Kozick | 1 | 1 |
| Ian B. Walters | 1 | 1 |
| Gregory B. Bailey | 1 | 1 |
| Andrea E. Park | 1 | 1 |
| Robert B. Glassman | 1 | 1 |
| Allan B. Shaw | 1 | 1 |
| Robert B. Kramer | 1 | 1 |
| Mark M. Simon | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.